Leerink Partnrs Brokers Decrease Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Leerink Partnrs decreased their Q4 2025 earnings per share estimates for ACADIA Pharmaceuticals in a report released on Thursday, July 10th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.13. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' FY2026 earnings at $0.45 EPS, FY2027 earnings at $0.95 EPS and FY2028 earnings at $1.65 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. The firm had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 17.46% and a net margin of 22.97%. The business's quarterly revenue was up 18.7% on a year-over-year basis. During the same period last year, the company earned $0.10 earnings per share.

Several other equities analysts also recently commented on ACAD. Cantor Fitzgerald upgraded ACADIA Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. JPMorgan Chase & Co. increased their price target on ACADIA Pharmaceuticals from $26.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, June 6th. UBS Group decreased their price target on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and increased their price target for the company from $20.00 to $35.00 in a research note on Wednesday, May 21st. Finally, Bank of America increased their price target on ACADIA Pharmaceuticals from $18.00 to $23.00 and gave the company a "hold" rating in a research note on Thursday, June 5th. Six investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $27.88.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock remained flat at $22.55 during trading hours on Monday. The company's stock had a trading volume of 1,820,726 shares, compared to its average volume of 1,977,143. The company has a market capitalization of $3.77 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 4.86 and a beta of 0.64. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $25.23. The business has a 50 day moving average of $21.48 and a 200 day moving average of $18.64.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue grew its stake in ACADIA Pharmaceuticals by 8.1% in the second quarter. State of Alaska Department of Revenue now owns 73,747 shares of the biopharmaceutical company's stock valued at $1,590,000 after acquiring an additional 5,522 shares during the period. Kingstone Capital Partners Texas LLC acquired a new stake in ACADIA Pharmaceuticals in the second quarter valued at approximately $336,000. Wealth Enhancement Advisory Services LLC acquired a new stake in ACADIA Pharmaceuticals in the second quarter valued at approximately $511,000. Pallas Capital Advisors LLC acquired a new stake in ACADIA Pharmaceuticals in the second quarter valued at approximately $273,000. Finally, Wesbanco Bank Inc. grew its stake in ACADIA Pharmaceuticals by 51.0% in the second quarter. Wesbanco Bank Inc. now owns 78,200 shares of the biopharmaceutical company's stock valued at $1,687,000 after acquiring an additional 26,400 shares during the period. Institutional investors and hedge funds own 96.71% of the company's stock.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Laura Brege sold 14,446 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the sale, the director owned 15,095 shares of the company's stock, valued at approximately $328,769.10. This trade represents a 48.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Mark C. Schneyer sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the sale, the executive vice president directly owned 62,130 shares of the company's stock, valued at $1,553,250. This trade represents a 3.12% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,271 shares of company stock valued at $525,079. Company insiders own 26.50% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.